International Journal of Radiation Oncology*Biology*Physics
Physics ContributionsPotential role of various dosimetric quality indicators in prostate brachytherapy
Introduction
Transperineal ultrasound guided prostate brachytherapy supported by sophisticated computerized treatment planning has emerged as a viable option in the management of early stage carcinoma of the prostate gland. Measured in terms of local control and freedom from biochemical failure, the results of conformal brachytherapy have been found to be as a favorable as the most positive radical prostatectomy series 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11. The wide spread acceptability and reproducibility of the favorable results cited will be dependent on appropriate patient selection, assignment to the appropriate treatment regimen and the ability of brachytherapists to reproduce the technical aspects of the procedure. Postoperative CT-based dosimetric analysis provides detailed information regarding the coverage and uniformity of an implant. It also affords the ability to compare various intraoperative techniques and provides a sound basis for future improvement. Recent detailed reports have been published by Willins and Wallner 12, 13, Merrick et al. 14, 15, Prestidge et al. 16, 17, Moerland et al. (18), and Stock et al. 19, 20, 21. A dose response curve for 125I ultrasound guided prostate brachytherapy has also recently been reported (21).
The assessment of implant quality, however, remains an unanswered and controversial issue. Bice and Prestidge (22) evaluated 23 previously described parameters of implant quality with the conclusion that “no single best assessment tool has been demonstrated for prostate brachytherapy.” They also concluded that assessment of implant quality should be based on dose-volume histogram analysis. Quality is easy to conceptualize but more difficult to quantitate. There is no disagreement that a good implant should cover the target volume, but there is no consensus as to what represents an adequate dose. The American Brachytherapy Society (ABS) has recently proposed that brachytherapy quality be measured in terms of the following parameters: D90, V100, and V150 (23). D90 is defined as the minimal dose covering 90% of the prostate volume and V100 and V150 are defined as the percent volume of the prostate receiving at least 100% or 150% of the prescribed minimal peripheral dose (mPD), respectively. V100 and V150 are identical with the parameters proposed by Saw and Suntharalingam, which they coined the Coverage Index and the Dose Nonuniformity Ratio (24). To date, no study has compared the relationships between these parameters at the same point in time after the implant procedure. Multiple postoperative dosimetric publications have evaluated either a V100 12, 14, 15, 18, 25, 26, a D90 19, 20, 21 or a D80 and D100 16, 17. Herein, we report detailed dosimetric evaluation for 60 consecutive prostate brachytherapy patients implanted via a standard transperineal ultrasound guided approach in terms of D90, D100, V90, V100, and V150 and also the maximal and average rectal and urethral dose.
Section snippets
Materials and methods
Sixty consecutive patients who underwent transperineal ultrasound guided conformal prostatic brachytherapy from early December 1997 through mid-May 1998 using either 125I1 or 103Pd2 for clinical T1/T2 carcinoma of the prostate gland were retrospectively evaluated. The choice of isotope was dependent upon Gleason score. Because of significant inaccuracy of Gleason grading, all cases originating from outside institutions were reviewed prior to formulation of a treatment plan (27). Thirty patients
Results
A summary of the dosimetry data is listed in Table 2. The postimplant CT prostate volumes were nearly the same as the planning volumes of Table 1. This allowed evaluation of the preplan execution: the mean V100 for the study was 94.1% volume compared to 99.5% volume in the preplans. The mean D90 was 107.8% of the mPD. 81.7% of the cohort (49/60) had a D90 exceeding the prescribed dose and all patients had a D90 exceeding 0.9 × mPD. The mean and minimum of the quality parameters D90 and V100
Discussion
The management of clinically organ confined carcinoma of the prostate gland remains one of significant controversy within the uro-oncology community. Prostate brachytherapy has emerged however, as a viable option for the treatment of early stage carcinoma of the prostate gland. Recent reports have reported that in terms of local control and freedom from biochemical failure, the results of conformal brachytherapy have been found to be as favorable as the most positive radical prostatectomy
References (36)
- et al.
Prostate specific antigen based disease control following ultrasound guided iodine-125 implantation for stage T1/T2 prostatic carcinoma
J Urol
(1995) - et al.
Short term freedom from disease progression after I-125 prostate implantation
Int J Radiat Oncol Biol Phys
(1994) - et al.
Pd-103 brachytherapy and external beam radiation therapy for clinically localized high risk prostatic carcinoma
Int J Radiat Oncol Biol Phys
(1996) - et al.
Brachytherapy and organ preservation in the management of carcinoma of the prostate
Sem Rad Oncol
(1993) - et al.
Long term outcomes of external beam irradiation and I-125/Pd-103 brachytherapy boost for prostate cancer
Int J Radiat Oncol Biol Phys
(1996) - et al.
Prostate specific antigen nadir of 0.5ng/ml or less defines disease freedom for surgically staged men irradiated for prostate cancer
Urology
(1997) - et al.
Transperineal ultrasound guided radioactive seed implantation for organ confined carcinoma of the prostate
Int J Radiat Oncol Biol Phys
(1997) - et al.
CT based dosimetry for transperineal I-125 prostate brachytherapy
Int J Radiat Oncol Biol Phys
(1997) - et al.
Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy
Int J Radiat Oncol Biol Phys
(1995) - et al.
Evaluation of permanent I-125 prostate implants using radiography and magnetic imaging
Int J Radiat Oncol Biol Phys
(1997)
Dose response for iodine-125 prostate implants
Int J Radiat Oncol Biol Phys
A dose response study for I-125 prostate implants
Int J Radiat Oncol Biol Phys
Quantitative assessment of interstitial implants
Int J Radiat Oncol Biol Phys
Quality assurance calibration of I-125 rapid strand in a sterile environment
Int J Radiat Oncol Biol Phys
A CT based evaluation method for permanent implantsApplication to prostate
Int J Radiat Oncol Biol Phys
The effect of local control on metastatic dissemination in carcinoma of the prostatelong term results in patients with I-125 implantation
Int J Radiat Oncol Biol Phys
Iodine-125 implants versus external beam therapy for stages A2, B, and C prostate cancer
Int J Radiat Oncol Biol Phys
Permanent implants using Au-198, Pd-103, and I-125radiobiological considerations based on the linear quadratic model
Int J Radiat Oncol Biol Phys
Cited by (72)
Permanent prostate brachytherapy using high V150
2015, Practical Radiation OncologyComparison of CT and MR-CT fusion for prostate post-implant dosimetry
2012, International Journal of Radiation Oncology Biology PhysicsBenchmarking dosimetric quality assessment of prostate intensity-modulated radiotherapy
2012, International Journal of Radiation Oncology Biology PhysicsCitation Excerpt :Again, risk status (p = .45), T stage (p = .77), use of neoadjuvant ADT (p = .96), and treatment date (p = .42) were not related to conformity. In the assessment of dosimetric quality using external beam RT, unlike permanent seed brachytherapy (24), no index has been correlated with the outcomes, consequently none have gained universal acceptance. Therefore, we believed it important to consider a wider perspective and, thus, assessed the coverage, homogeneity, and conformity separately.
A rationale for developing benchmarks for the treatment of muscle-invasive bladder cancer
2007, Urologic Oncology: Seminars and Original Investigations